본문 바로가기

Effects of Rituximab Including Long-term Maintenance Therapy in Children with Nephrotic Syndrome in a Single Center of Korea

문서 유형
연구출판물 · 학술지 논문
등재
KCI
저널
Childhood Kidney Diseases22(1) · pp.1 · 2018
피인용
KCI 0
ISSN
2384-0242

저자

  1. 김성헌제1저자Department of Pediatrics, Pusan National University Children’s Hospital, Yangsan, Korea
  2. 임택진Department of Pediatrics, Pusan National University Children’s Hospital, Yangsan, Korea
  3. 송지연Department of Pediatrics, Pusan National University Children’s Hospital, Yangsan, Korea
  4. 김수영교신저자Department of Pediatrics, Pusan National University Children’s Hospital, Yangsan, Korea

초록

Rituximab (RTX) is a chimeric monoclonal antibody that inhibits CD20-mediated B-cell proliferation and differentiation. Several studies have examined its use in intractable nephrotic syndrome (NS) with some positive results. However, those studies examined such effects for a short-term period of 1 year, and some patients continued to relapse after a lapse in RTX treatment. Our use of RTX as a maintenance therapy (RTX injection when the CD19 cell count exceeded 100–200/μL before relapse) showed some noticeable efficacy. We used RTX in 19 patients with steroid-dependent NS (SDNS). In 12 patients treated with RTX maintenance therapy, only one relapse occurred. The mean treatment period was 23.4±12.7 months, and the mean number of RTX administrations was 3.9±1.6. The relapse rates were decreased (from 2.68/year to 0.04/year), and the drug-free period also increased (from 22.5 days/year to 357.1 days/year) during maintenance therapy. The other seven patients were treated with one cycle of RTX or additional cycles in case of relapse (non-maintenance therapy). Relapse rates were significantly decreased after RTX treatment (from 1.76/year to 0.96/year, P =0.017). The relapsefree period was 15.55±7.38 (range, 5.3–30.7) months. No severe side effects of RTX were found except for a hypersensitivity reaction such as fever and chills during its infusion. In conclusion, RTX is considered an effective and safe option to reduce the relapse rate by a single- or maintenance-interval therapy in SDNS.

키워드

Nephrotic syndromeChildrenRituximabSteroid-dependent

식별자

KCI
ART002338336